← Sites

718 (USA)

USA PI: Dr. Nolan activated KRI 0.05
Patients
13
Active (enrolled/consented)
0
Withdrawn
2
Serious AEs
2
Open QA findings
0
Aged data queries
0

Studies & contracts total budget 168500.00 USD

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
Phase II study completed contract executed 168500 USD

Patients first 13

RefStatusConsentedStudy
718-1066 completed 2013-07-07 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
718-1079 completed 2012-09-19 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
718-1101 completed 2013-02-17 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
718-1139 completed 2013-05-19 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
718-1150 completed 2013-01-19 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
718-1170 completed 2013-09-16 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
718-1172 withdrawn 2013-09-21 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
718-1250 completed 2013-09-21 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
718-1254 completed 2013-07-10 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
718-1328 withdrawn 2013-02-01 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
718-1355 completed 2013-02-28 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
718-1371 completed 2013-04-26 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
718-1427 completed 2012-12-17 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.

Luna participants (0)

No participants at this site use Luna yet.

Safety 91 AEs · 2 serious

serious 718-1170 reported

Severe SYNCOPE — outcome: RECOVERED/RESOLVED; onset 2013-10-12 (study day 27.0); relationship: PROBABLE; serious criteria: hospitalization

serious 718-1371 reported

Severe PARTIAL SEIZURES WITH SECONDARY GENERALISATION — outcome: RECOVERED/RESOLVED; onset 2013-06-02 (study day 38.0); relationship: NONE; serious criteria: hospitalization

QA findings 0 open

No findings recorded.

Monitoring visits (0)

No visits recorded.

Payments (0)

No payments on file.